Eurofins Scientific SEWBO:ESF +0.70%77 Quick Ratio is 1.03 as of Dec. 2025, which is 14% below its 10-year median of 1.20. GuruFocus rates WBO:ESF with a GF Score™ of 77/100 and a GF Value™ of €66.89 (Fairly Valued). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Eurofins Scientific SE ranks worse than 70.23% on this metric.
Eurofins Scientific SE has a quick ratio of 1.03. It generally indicates good short-term financial strength.
The historical rank and industry rank for Eurofins Scientific SE's Quick Ratio or its related term are showing as below:
WBO:ESF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.96 Med: 1.2 Max: 2.17
Current: 1.03
During the past 13 years, Eurofins Scientific SE's highest Quick Ratio was 2.17. The lowest was 0.96. And the median was 1.20.
WBO:ESF's Quick Ratio is ranked worse than 70.23% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.67
vs WBO:ESF: 1.03
Eurofins Scientific SE (WBO:ESF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Eurofins Scientific SE Quick Ratio Related Terms
Eurofins Scientific SE Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Eurofins Scientific SE's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eurofins Scientific SE Quick Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Eurofins Scientific SE's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Eurofins Scientific SE's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Eurofins Scientific SE's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eurofins Scientific SE (WBO:ESF) has a Quick Ratio of 1.03 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eurofins Scientific SE and its competitors. This is 14% below median its historical median of 1.20. Over the past decade, Eurofins Scientific SE's Quick Ratio has ranged from 0.96 to 2.17. According to the industry distribution chart, Eurofins Scientific SE ranks #151 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 70.2%.
Is Eurofins Scientific SE's Quick Ratio too high?
Eurofins Scientific SE's current Quick Ratio of 1.03 is 14% below median its 10-year median of 1.20. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 2.17. The Medical Diagnostics & Research industry median Quick Ratio is 1.67. Eurofins Scientific SE's value of 1.03 is 38.3% below this industry median. Based on the distribution chart, Eurofins Scientific SE ranks #151 out of 215 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Eurofins Scientific SE has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Eurofins Scientific SE's Quick Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Eurofins Scientific SE ranks #151 out of 215 companies for Quick Ratio. This places Eurofins Scientific SE in the lower half of its industry. The industry median Quick Ratio is 1.67. Eurofins Scientific SE's value of 1.03 is 38.3% below this benchmark. Historically, Eurofins Scientific SE's own Quick Ratio has ranged from 0.96 to 2.17 over the past decade. While the company's 10-year median is 1.20 vs. the industry median of 1.67, Eurofins Scientific SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Diagnostics & Research company?
The median Quick Ratio among Medical Diagnostics & Research companies is 1.67, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eurofins Scientific SE's current Quick Ratio of 1.03 is 38.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Eurofins Scientific SE and its competitors. For the Medical Diagnostics & Research industry, the median Quick Ratio is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eurofins Scientific SE's current Quick Ratio is 1.03, which is 14% below median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eurofins Scientific SE stock overvalued right now?
Based on GuruFocus' analysis, Eurofins Scientific SE (WBO:ESF) is currently considered Fairly Valued. The stock's GF Value™ is €66.89, compared to a current price of €68.70 — trading 2.7% above its estimated fair value. The current Quick Ratio is 1.03, which is 14% below median its 10-year median of 1.20 and 38.3% below the Medical Diagnostics & Research industry median of 1.67. Eurofins Scientific SE's overall GF Score™ is 77/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Eurofins Scientific SE (WBO:ESF), the current Quick Ratio is 1.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eurofins Scientific SE (WBO:ESF) Overvalued in 2026?
Based on GuruFocus' analysis, Eurofins Scientific SE stock appears to be overvalued.
The current stock price of €68.70 is trading 2.7% above its estimated GF Value™ of €66.89.
GuruFocus considers Eurofins Scientific SE to be Fairly Valued.
Key valuation signals for WBO:ESF:
Quick Ratio: 1.03 (14% below median its 10-year median of 1.20)
GF Value™: €66.89 vs. price of €68.70 (2.7% above fair value)
Industry Position: 38.3% below the Medical Diagnostics & Research median (#151 of 215)
No single metric tells the full story. See the WBO:ESF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eurofins, headquartered in Luxembourg, is a decentralized network of life sciences companies that provide various analytical tests and laboratory services. These include tests to evaluate the safety, identity, composition, authenticity, purity, origin, and traceability of various biological substances and products. Eurofins operates over 950 laboratories in 61 countries. Its revenue from Europe, North America, and the rest of the world contributes approximately 50%, 40%, and 10% of total revenue, respectively. Its areas of business activity are food, feed, and environmental testing ("life"), biopharmaceutical services, diagnostic services and products, and consumer and technology products testing, which contribute approximately 40%, 30%, 20%, and 10% respectively.
77GF Score
Get the complete analysis for WBO:ESF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ESF has been successfully added to your 
